Summary
- Profile Type
- Business Offer
- POD Reference
- BOGR20240423006
- Term of Validity
- 23 April 2024 - 23 April 2025
- Company's Country
- Greece
- Type of partnership
- Commercial agreementInvestment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
This is a Digital Precision Medicine company bringing objective and passive measurement to reinvent the way we diagnose, monitor, and care for mental health.
The company is backed by top-tier investors (e.g. Felicis) and partners with some of the largest Pharma/Life Science companies (e.g. Janssen, Biogen, IQVIA) to develop novel digital biomarkers and bring data-driven Drug+ and DTx solutions to market as standalone or alongside medications. - Full Description
-
One out of four individuals will experience a mental disorder. The WHO estimates that mental illness will be the leading cause of disability by 2030. Yet, while other medical practices have been using objective measurement tools for decades, when it comes to mental conditions, we still rely on self-reported questionnaires to make diagnosis or treatment decisions. For pharma, this lack of continuous, objective measurement is reflected in low drug approvals and high failure rates more broadly in CNS. Over 50% of patients with mental health issues also do not adhere to treatment. Mental health also presents itself as a comorbidity to most chronic conditions. In Oncology, for example, depression increases mortality rates by up to 39%, and only 51% of patients suffering from depression commenced chemotherapy. Additionally, >70% of oncologists and 85% of patients believe that mood affects cancer progression.
This Digital Precision Medicine platform is an integrated ecosystem that collects physiological and digital data continuously (and passively) in a multi-modal approach from a plethora of sources including wearable devices, voice, video, and text data, data from the sensors of the mobile phone, and other clinician and patient reported outcomes. We go a step further by utilizing our algorithmic platform to then translate this data into meaningful and explainable measures in mental health, with a series of measures already in our platform related to mood, stress, sleep, physical activity, psychomotor activity, social activity, etc. Furthermore, we integrate these measures into digital health programs either alongside medications (Drug+ patient support) or standalone (DTx).
This Digital Precision Medicine platform allows us to work with pharma across the lifecycle of an asset - in clinical and RWE studies to generate evidence and for the exploration of novel digital endpoints, and for the development of companion digital health/patient support programs alongside medications. We partner directly with large pharmaceutical companies offering our Digital Precision Medicine Platform for evidence generation (patient monitoring and digital endpoint development), as well as patient engagement, retention, and profiling. These pharma partnerships evolve into Drug+ programs where our solution goes to market alongside a medication when it launches commercially. Here we offer adherence support, relapse prediction, and patient support. - Advantages and Innovations
-
Technology & Biobank:
•Algorithms & Digital Biomarkers: Proprietary patented technology (algorithms) that can detect changes in the emotional state of an individual using physiological and digital data (results have been validated and published). A series of additional digital and physiological markers have been developed and validated around sleep, stress, psychomotor and social activity.
•Wearable device built in-house that includes a proprietary GSR sensor (in addition to PPG, Skin Temperature, Accelerometer, Ambient Humidity & Temperature sensors), which doesn’t exist in most consumer devices on the market but which is crucial for monitoring changes in the ANS and for mental health monitoring overall
•Multimodal approach that collects data from wearables (ours and 3rd party), sensors of the mobile phone of the user (GPS, Bluetooth, Accelerometer) and voice/video/text.
•Continuous and passive monitoring of mental and behavioral health with the goal of creating the largest digital biobank in the space (over 3,000 users already on our platform)
•Large-scale Machine Learning Experimentation Platform and algorithmic capabilities that allow us to develop and validate digital biomarkers and endpoints for mental/behavioral health
Subject Matter Expertise: Thought leadership and therapeutic area expertise in mental and behavioral health
Commercial: Established strategic partnerships with key channels in place (e.g., Pharma, CROs) that allow us to uniquely move from clinical data to clinical practice - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
- Business matchmaking
- Type and Size of Partner
- OtherBig companySME 50 - 249
- Type of partnership
- Commercial agreementInvestment agreement
Call details
- Coordinator required
-
Yes
Dissemination
- Market keywords
- 05001001 - Diagnostic services05003001 - Therapeutic services05003006 - Other therapeutic (including defibrillators)
- Targeted countries
- All countries